Daptomycin for methicillin-resistant Staphylococcus aureus infections of the spine.
BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) infection is increasingly common. Treatment with vancomycin-based therapy is often unsuccessful. Daptomycin is a relatively new lipopeptide antibiotic with potent activity against MRSA. PURPOSE: To describe the successful management of MRSA infection involving the spine. STUDY DESIGN: Two case reports of MRSA infection, one involving epidural and lumbar subdural abscesses, the other with osteomyelitis and discitis. METHODS: Two cases are described, one with lumbar epidural and subdural abscesses and the other with osteomyelitis and discitis of the spine. Switching from vancomycin to daptomycin plus rifampin-based therapy resulted in patient improvement that allowed discharge from the hospital. RESULTS: Both patients recovered fully from their infection. CONCLUSIONS: Daptomycin is a safe and effective option for the treatment of MRSA infection involving the spine.[1]References
- Daptomycin for methicillin-resistant Staphylococcus aureus infections of the spine. Burdette, S.D. Spine. J (2009) [Pubmed]
Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenesOpen Access LicencePrivacy PolicyTerms of Useapsburg
